Eterna Therapeutics Inc share price logo

Eterna Therapeutics Inc Share Price

NASDAQ: ERNA

Small Cap

$0.22

-0.02

(-7.79%)

Live

as on

Eterna Therapeutics Inc Stock Performance

as on March 25, 2026 at 4:10 am IST

  • Day's High

    $0.22
    $0.23

    4.55%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.26
    $4.05
    downward going graph

    -16.55%

    Downside

    1740.23%

    Upside

    downward going graph

Eterna Therapeutics Inc share price movements today

Previous Close
$0.23
Open
$0.23
Volume
1.0M
Day's Low - High
$0.22 - $0.23
52 Week Low - High
$0.26 - $4.05

Eterna Therapeutics Inc Historical Returns

1 Month Return
-1.7 %
3 Month Return
-78.57 %
1 Year Return
-93.3 %
3 Year Return
-99.46 %
5 Year Return
0 %

Eterna Therapeutics Inc Stock Fundamentals & Key Indicators

Check Eterna Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$7.2M

EPS (TTM)

0

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

Industry PE ratio

0

PEG Ratio

0

EBITDA

-9.3M

Revenue (TTM)

1.0K

Profit Margin

0.00%

Return On Equity TTM

-686.69%

Eterna Therapeutics Inc Stock Valuation

Track how Eterna Therapeutics Inc P/E has moved over time to understand its valuation trends.

Eterna Therapeutics Inc in the last 5 years

  • Overview

  • Trends

Lowest (-9.75x)

March 31, 2023

Industry (0.00x)

March 23, 2026

Today (0.00x)

March 23, 2026

Highest (-0.49x)

September 30, 2025

LowHigh

Today’s Price to Earnings Ratio: 0.00x

Eterna Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Eterna Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Eterna Therapeutics Inc image
Eterna Therapeutics Inc
SELL$7.2MNANA0.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$41.4B125.13%133.418.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$115.3B112.56%29.6732.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$31.6BNA1115.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$77.5B56.01%17.6731.41%

Stock Returns calculator for Eterna Therapeutics Inc Stock including INR - Dollar returns

The Eterna Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Eterna Therapeutics Inc investment value today

Current value as on today

₹15,082

Returns

₹84,918

(-84.92%)

Returns from Eterna Therapeutics Inc Stock

₹94,458 (-94.46%)

Dollar Returns*

₹9,541 (+9.54%)

Analyst Recommendation on Eterna Therapeutics Inc Stock

Based on 6 analysts

SELL

0.00%

Buy

50.00%

Hold

50.00%

Sell

Based on 6 analysts, 50% of analysts recommend a 'SELL' rating for Eterna Therapeutics Inc. Average target price of $3

Eterna Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Eterna Therapeutics Inc.

What analysts predicted

92.67%UPSIDE

Target Price

$3

Current Price

$0.22

Analyzed by

6 Analysts

Target

$3.00

Eterna Therapeutics Inc target price $3, a slight upside of 92.67% compared to current price of $0.22. According to 6 analysts rating.

Eterna Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Eterna Therapeutics Inc Stock has decreased by -63% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-63% versus previous 30 day period

Eterna Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Total Revenue
0
0
0
0
0
0
-
-
-
Gross Profit
0
0
0
0
0
0
0
0
-
Operating Income
-5
-5
-5
-4
-2
-2
-2
-2
-1
EBITDA
-4
-5
-5
-4
-24
-2
-2
-2
-1
Interest Expense
0
0
0
0
1
3
0
-
0
Depreciation
0
0
0
0
0
0
0
0
0
Income Before Tax
-5
-6
-6
-5
-26
-5
-8
-3
-1
Income Tax Expense
0
0
0
0
0
0
0
0
0
Net Income
-5
-6
-6
-5
-26
-5
-8
-3
-1
Net Profit Margin
-10962.75%
-36194.12%
-14142.55%
-11763.83%
-5462.83%
-575900.00%
0.00%
0.00%
0.00%

Eterna Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Total Revenue
22
21
23
19
5
-
-
0
0
Gross Profit
14
14
14
11
0
0
0
0
0
Operating Income
-2
-1
0
-1
-7
-113
-33
-21
-15
EBITDA
0
0
3
1
-26
-121
-24
-19
-36
Interest Expense
0
0
0
0
0
0
0
0
6
Depreciation
-
-
-
-
0
0
0
0
1
Income Before Tax
-2
-1
0
-2
-26
-122
-24
-21
-44
Income Tax Expense
0
0
0
0
-19
0
0
0
0
Net Income
-2
-1
0
-2
11
-122
-24
-21
-44
Net Profit Margin
-13.10%
-5.06%
-1.11%
-10.34%
205.28%
0.00%
0.00%
-31864.71%
-7652.75%

Eterna Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-6
-6
-5
-26
-5
-8
-3
-1
-1
Operating Cash Flow
-4
-3
-2
-6
-3
-2
-2
-1
-1
Investing Cash Flow
0
0
0
0
-
-
-
0
0
Financing Cash Flow
7
1
0
3
1
2
4
0
-7
Change in Cash
3
-2
-2
1
-2
0
2
-1
-1

Eterna Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-1
0
-2
-26
-122
-24
-21
-44
-14
Operating Cash Flow
0
1
2
-8
-23
-20
-20
-15
-7
Investing Cash Flow
-1
-1
-1
0
-22
0
0
0
0
Financing Cash Flow
-1
0
-1
4
61
19
16
6
7
Change in Cash
-2
0
0
-1
15
-1
-3
-9
0

Global Institutional Holdings in Eterna Therapeutics Inc

Funds
Holdings
Genworth Financial Wealth Mgmt Inc
0%
CI Private Wealth LLC
1.62%
Geode Capital Management, LLC
0.08%
Bank of America Corp
0%
Genworth Financial Wealth Mgmt Inc
0%
See all

Insights on Eterna Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 11.4% return, outperforming this stock by 105.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Eterna Therapeutics Inc has experienced a drawdown of -99.5%, however Alnylam Pharmaceuticals, Inc. resisted the overall trend and outperformed by 89.3%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, ERNA stock has moved down by -18.8%

About Eterna Therapeutics Inc

brooklyn is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases. brooklyn’s most advanced program is irx-2, a human cell-derived cytokine therapy, studying the safety and efficacy of irx-2 in patients with head and neck cancer in phase 2b. in a phase 2a clinical trial in head and neck cancer, irx-2 demonstrated an overall survival benefit. additional studies are either underway or planned in other solid tumor cancer indications. brooklyn has multiple next-generation cell and gene-editing therapies in preclinical development for various indications including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. for more information about brooklyn and its clinical programs, please visit www.brooklynitx.com.
OrganisationEterna Therapeutics Inc
Headquarters1035 Cambridge Street, Cambridge, MA, United States, 02141
IndustryHealthcare
CEOMr. Sanjeev Luther
E-voting on sharesClick here to vote

Key Management of Eterna Therapeutics Inc

Name

Title

Dr. Robert Hamilton Pierce M.D.

Chief Scientific Officer

Ms. Dorothy J. Clarke

General Counsel

Dr. Kanika Chawla Ph.D.

Senior Vice President of Technical Operations (Consultant)

Mr. Sanjeev Luther

CEO, President & Director

Ms. Sandra M. Gurrola

Senior VP of Finance

FAQs

What is Eterna Therapeutics Inc share price today?

Eterna Therapeutics Inc share price today is $0.22 as on . Eterna Therapeutics Inc share today touched a day high of $0.23 and a low of $0.22.

What is the 52 week high and 52 week low for Eterna Therapeutics Inc share?

Eterna Therapeutics Inc share touched a 52 week high of $4.05 on and a 52 week low of $0.26 on . Eterna Therapeutics Inc stock price today i.e. is trending at $0.22,which is 94.57% down from its 52 week high and -14.20% up from its 52 week low.

What is Eterna Therapeutics Inc's market capitalisation today?

Eterna Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Eterna Therapeutics Inc Stock (ERNA) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Eterna Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Eterna Therapeutics Inc Shares that will get you 6.8182 shares as per Eterna Therapeutics Inc share price of $0.22 per share as on March 24, 2026 at 10:40 pm IST.

What is the minimum amount required to buy Eterna Therapeutics Inc Stock (ERNA) from India?

Indian investors can start investing in Eterna Therapeutics Inc (ERNA) shares with as little as ₹93.734 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹937.34 in Eterna Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Eterna Therapeutics Inc share’s latest price of $0.22 as on March 24, 2026 at 10:40 pm IST, you will get 45.4545 shares of Eterna Therapeutics Inc. Learn more about fractional shares .